Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension

被引：0

作者：

Judd, Eric ^{[1
]}

Jaimes, Edgar A. ^{[2
]}

机构：

[1] Univ Alabama Birmingham, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Div Nephrol, ZRB 637,1530 3rd Ave South, Birmingham, AL 35294 USA

来源：

EXPERT REVIEW OF CARDIOVASCULAR THERAPY | 2012年 / 10卷 / 03期

关键词：

aliskiren; amlodipine; angiotensin II; antihypertensive medications; cardiovascular disease; combination therapy; hypertension; renin;

D O I：

10.1586/ERC.12.7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular-related morbidity and mortality is linked to hypertension with proportional gains in cardiovascular risk factor reduction with the lowering of blood pressure. Clinical trial data has shown that attaining goal blood pressure requires, for most patients, at least two antihypertensive medications, with a significant proportion requiring regimens of three or more medications. Single-pill triple combinations have returned to the market following results of increased efficacy and adherence over dual-and mono-therapy. The combination of aliskiren, amlodipine and hydrochlorothiazide is a rational choice for combination therapy and recent studies suggest that it is safe and effective in lowering blood pressure in patients who fail dual combination therapy.

引用

页码：293 / 303

页数：11

共 63 条

[1] Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
Andersen, Karl
Weinberger, Myron H.
Egan, Brent
Constance, Christian M.
Ali, Mohammed A.
Jine, James
Keefe, Deborah L.
[J]. JOURNAL OF HYPERTENSION, 2008, 26 (03) : 589 - 599
[2] Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
Azizi, M
Ménard, J
Bissery, A
Guyenne, TT
Bura-Rivière, A
Vaidyanathan, S
Camisasca, RP
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12): : 3126 - 3133
[3] Barrios V, 2010, EXPERT REV CARDIOVAS, V8, P1609, DOI [10.1586/erc.10.115, 10.1586/ERC.10.115]
[4] Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study
Basile, Jan
Babazadeh, Simon
Lillestol, Michael
Botha, Jaco
Yurkovic, Carol
Weitzman, Richard
[J]. JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (03) : 162 - 169
[5] Comparative Efficacy and Safety of Combination Aliskiren/Amlodipine and Amlodipine Monotherapy in African Americans With Stage 2 Hypertension
Black, Henry R.
Weinberger, Myron H.
Purkayastha, Das
Lee, Joleen
Sridharan, Kanaka
Israel, Marc
Hilkert, Robert
Izzo, Joseph
[J]. JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (08) : 571 - 581
[6] Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double-Blind Study
Black, Henry R.
Kribben, Andreas
Aguirre Palacios, Fernando
Bijarnia, Mahendra
Laflamme, Annik K.
Baschiera, Fabio
[J]. JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (12) : 917 - 926
[7] Triple Fixed-Dose Combination Therapy Back to the Past
Black, Henry R.
[J]. HYPERTENSION, 2009, 54 (01) : 19 - 22
[8] Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial
Brown, Morris J.
McInnes, Gordon T.
Papst, Cheraz Cherif
Zhang, Jack
MacDonald, Thomas M.
[J]. LANCET, 2011, 377 (9762) : 312 - 320
[9] Buczko W, 2008, PHARMACOL REP, V60, P623
[10] Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide A Randomized Clinical Trial
Calhoun, David A.
Lacourciere, Yves
Chiang, Yann Tong
Glazer, Robert D.
[J]. HYPERTENSION, 2009, 54 (01) : 32 - 39

← 1 2 3 4 5 6 7 →